Sonova Raises Full-Year Outlook Following Strong Growth in Hearing Aid Sales

Image
HHTM
November 17, 2026

STÄFA, SWITZERLAND — Sonova reported strong growth in hearing aid sales during the first half of its 2026/27 financial year, supported by demand for newer Phonak products, expanded relationships with major customers, and increased deliveries to the U.S. Department of Veterans Affairs (VA).

The Swiss hearing technology company, whose brands include Phonak, Unitron, and Advanced Bionics, reported total sales of CHF 1.83 billion (~$2.18B USD) for the six months ending September 30, 2026, representing an increase of 7.5% in local currencies compared with the same period last year.

Sonova’s hearing aid business performed particularly well, while its cochlear implant division continued to face challenges in the United States and China. Based on the stronger overall results, the company raised its expectations for sales and profit growth for the remainder of its financial year.

Phonak Hearing Aid Sales Drive Growth

Sonova’s Hearing Instruments division, which includes hearing aid manufacturing and its retail hearing care operations, generated CHF 1.72 billion (~$2.05 billion) in sales during the six-month period, an increase of 9.0% in local currencies.

Sales to hearing care professionals, distributors, and other wholesale customers increased 11.0%, while the company’s retail hearing care business grew 6.5%.

According to Sonova, its wholesale hearing aid business has now gained market share for 11 consecutive quarters, reflecting continued demand for its products and expanded commercial relationships.

Much of the growth was supported by Phonak’s recent hearing technology portfolio, including Virto R and Infinio Ultra. The newer Phonak Audéo EON platform also began contributing to sales toward the end of the reporting period.

EON incorporates updated artificial intelligence-based sound processing in a smaller, lighter hearing aid design. Sonova highlighted improvements in speech understanding, connectivity, wind noise management, and battery performance as key features of the platform.

“Our innovation leadership is delivering meaningful advances in hearing performance and experience with EON, Roger On Sphere and Integro. EON is already contributing above our expectations, combining superior acoustics in a smaller device with best-in-class connectivity – its launch across our markets supported growth and market share gains”

–Eric Bernard, CEO of Sonova

The company also highlighted Roger On Sphere, its newer remote microphone technology designed to support speech understanding across distances and in challenging environments involving multiple speakers.

phonak roger on sphere

North American Growth and VA Demand

North America remained an important contributor to Sonova’s performance, with regional sales increasing 7.5% in local currencies to CHF 654.3 million (~$779 million).

Growth was driven primarily by hearing aid sales, including stronger demand from major commercial customers and increased deliveries to the U.S. Department of Veterans Affairs.

The VA represents a significant market for hearing aid manufacturers because of the large number of veterans receiving hearing healthcare through the federal system.

Image

Sonova also reported growth across Europe, Latin America, and Asia Pacific. Sales in Asia Pacific increased 11.4%, supported by demand for hearing aids in Australia, China, and Japan.

The company estimated that the global hearing aid market grew approximately 5% during the first half of its financial year, with stronger growth during the second quarter.

Sonova’s retail hearing care operations also expanded through acquisitions, including Harbor Audiology, a hearing care provider based in Washington State, and Høreservice Danmark, a Danish provider specializing in mobile hearing care services.

Cochlear Implant Business Faces Continued Challenges

While hearing aid sales increased, Sonova’s Advanced Bionics cochlear implant business experienced a more difficult first half.

Sales in the Cochlear Implants division declined 10.2% in local currencies to CHF 117.4 million (~$140 million).

The company attributed the decline primarily to lower cochlear implant system sales in China and the United States, along with reduced sales of processor upgrades and accessories.

In China, changes to government purchasing arrangements have placed pressure on cochlear implant sales. Sonova also reported that some customers delayed processor upgrades ahead of the introduction of newer technology.

Advanced Bionics introduced its Integro cochlear implant sound processor in Europe in October 2026 following regulatory approval. The processor incorporates Phonak AI-based technology, improved sound localization capabilities, and Roger connectivity.

Its U.S. introduction remains subject to FDA approval.

Despite the overall decline, Sonova reported cochlear implant sales growth in several markets, including Canada, Brazil, India, and parts of Europe.

Higher Profitability and Improved Outlook

Sonova also reported improved profitability during the period, reflecting increased hearing aid sales, higher average selling prices, and efforts to manage operating costs.

Core operating profit, a measure of earnings from the company’s ongoing business activities that excludes certain exceptional expenses, increased 22.9% in local currencies to CHF 384 million (~$457 million).

The stronger performance prompted Sonova to raise its financial outlook for the full 2026/27 fiscal year.

The company now expects overall sales growth of 6% to 8%, compared with its previous forecast of 5% to 8%. It also expects core operating profit to increase by 10% to 13%, up from its earlier forecast of 7% to 10%. Both forecasts are measured in local currencies.

Sonova also increased its estimate for overall hearing aid market growth during the financial year to 3% to 5%, compared with its previous expectation of 2% to 4%.

Separately, the company said its planned divestment of its Consumer Hearing business remains on track for completion during the 2026/27 financial year. The business includes consumer audio products and is being separated from Sonova’s core hearing healthcare operations.

 

Source: Sonova Holding AG. (November 12, 2026). Sonova HY 2026/27 Results: Raising Full-Year Guidance After Strong First Half.

Email Marketing by Benchmark